Abstracts tagged "corticosteroids and glucocorticoids"

Abstract Number: 288 • 2018 ACR/ARHP Annual Meeting
Burden of Illness of Treating Patients with Pemphigus vulgaris
Jennie H. Best, Margaret Michalska and Ibrahim Abbass, Genentech, Inc., South San Francisco, CA
Background/Purpose: Pemphigus vulgaris (PV) is a rare autoimmune disorder that affects the skin and mucous membranes. Many patients with PV suffer from serious infections, and…
Abstract Number: 758 • 2016 ACR/ARHP Annual Meeting
Relationship Between Corticosteroids and Adverse Events in SLE –Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
Sharzad Emamikia¹, Cidem Gentline², Magnus Backheden³, Katerina Chatzidionysiou², Laurent Arnaud⁴ and Ronald F. van Vollenhoven^2,5, ¹Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Unit for Medical Statistics, Stockholm, Sweden, ⁴Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Dept. of Medicine, Karolinska institutet, Stockholm, Sweden, ⁵Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Corticosteroids (CSs) are widely used in Systemic Lupus Erythematosus (SLE) patients, but have side-effects when used for prolonged periods of time. Our aim was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].